Overview

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2029-05-01

Target enrollment:

Participant gender:

Summary

This is an open-label, phase 2, randomized study of intravesical N-803 plus BCG (experimental arm A) and intravesical N-803 plus gemcitabine (experimental arm B) in participants who have intermediate-risk Ta/T1 papillary disease. The primary objective of this study is to evaluate the efficacy of these experimental therapies without the need for surgical intervention by CR rate at month 3 or month 6 (for re-inducted participants).

Phase:

PHASE2

Details

Lead Sponsor:

ImmunityBio, Inc.

Treatments:

ALT-803
Gemcitabine